List of Excipients in Branded Drug MICONAZOLE NITRATE

Generic Drugs Containing MICONAZOLE NITRATE

Company	Ingredient	NDC	Excipient
Actavis Pharma Inc	miconazole nitrate	0472-1738	HYDROGENATED PALM KERNEL OIL
Cosette Pharmaceuticals Inc	miconazole nitrate	0713-0197	HYDROGENATED COCONUT OIL
Cosette Pharmaceuticals Inc	miconazole nitrate	0713-0252	BENZOIC ACID

What are the Most Frequently-Used Excipients in MICONAZOLE NITRATE?

# Of NDCs	Excipient
7	BENZOIC ACID
1	BHT
2	BUTYLATED HYDROXYANISOLE

Miconazole Nitrate Excipient Strategy and Commercial Opportunities

Last updated: August 27, 2026

Miconazole nitrate is an established imidazole antifungal with low active-ingredient cost, broad generic availability, and limited meaningful patent protection in major markets. Commercial differentiation depends primarily on formulation performance, tolerability, dose convenience, packaging, regulatory positioning, and channel access. The strongest opportunities are vaginal delivery systems, skin formulations for sensitive or high-friction areas, pediatric oral gel outside the United States, combination products, and premium products with improved adherence or reduced mess.

What dosage forms use miconazole nitrate?

Miconazole nitrate is marketed mainly in topical, vaginal, oral, and buccal formulations. The active concentration and excipient system depend on the route.

Dosage form	Typical strength	Primary use	Commercial status
Vaginal cream	2%	Vulvovaginal candidiasis	OTC and generic
Vaginal suppository or ovule	100 mg, 200 mg, 1,200 mg	Vulvovaginal candidiasis	OTC and generic
Topical cream	2%	Tinea, cutaneous candidiasis, athlete's foot	OTC and generic
Topical powder or spray	Usually 2%	Moist skin areas and foot infections	Market-dependent
Oral gel	2%	Oral candidiasis	Available in several non-U.S. markets
Buccal tablet	50 mg	Oropharyngeal candidiasis	Limited commercial availability
Combination vaginal product	Variable	Candidiasis with symptom relief or bacterial coverage	Country-specific

In the United States, miconazole nitrate vaginal products are regulated under the FDA's OTC vaginal antifungal monograph framework. Topical products are generally marketed under the OTC topical antifungal monograph when the formulation and labeling meet applicable requirements.[1,2]

Which excipients are used in miconazole nitrate formulations?

The most common excipient functions are solubilization, dispersion, emulsion stabilization, moisture control, preservative protection, pH adjustment, suppository structure, and skin feel.

Topical cream excipients

A 2% miconazole nitrate cream commonly uses a semisolid emulsion or cream base. Representative excipient classes include:

• Purified water
• Liquid paraffin or mineral oil
• White petrolatum
• Stearyl alcohol or cetostearyl alcohol
• Glyceryl stearate
• Polyethylene glycol stearates
• Propylene glycol
• Polysorbates
• Sorbitan esters
• Preservatives such as benzoic acid or related systems
• pH adjusters and chelating agents

The commercial objective is to keep miconazole nitrate uniformly dispersed while delivering acceptable spreadability and residence time. The active is poorly water-soluble, so a conventional aqueous cream typically uses a dispersed solid phase rather than relying on complete molecular dissolution.

A high-value formulation target is a low-grease, fast-spreading cream that maintains drug delivery under sweating, occlusion, or repeated washing. Mineral oil and petrolatum provide occlusivity but can reduce cosmetic acceptability. Silicone or ester-based alternatives can improve skin feel, but their compatibility with the active, preservative system, and packaging must be established.

Vaginal cream excipients

Vaginal creams often use a water-miscible or emulsified base containing:

• Purified water
• Mineral oil or liquid paraffin
• Cetostearyl alcohol
• Glyceryl monostearate
• Polyethylene glycol derivatives
• Propylene glycol
• Polysorbates
• Preservatives
• Buffering agents

The key technical issue is balancing drug release with vaginal retention. A base that is too hydrophilic may release the drug quickly but drain rapidly. A highly occlusive base may improve retention but create mess, leakage, or poor patient acceptance.

Vaginal products also require close control of osmolality, pH, preservative exposure, and compatibility with latex condoms or diaphragms. Oil-based vaginal products can weaken latex barrier devices. This warning is present on U.S. miconazole vaginal product labeling and materially affects product positioning.[3]

Vaginal suppository and ovule excipients

Suppositories typically use a lipid or polyethylene glycol matrix.

Base type	Advantages	Risks and development issues
Hard fat or triglyceride base	Melts at body temperature; familiar manufacturing process	Leakage, polymorphism, sensitivity to storage temperature
Semi-synthetic glycerides	Controlled melting and good molding behavior	Requires compatibility and release optimization
Polyethylene glycol base	Better physical stability and lower leakage	Can be hygroscopic and may irritate sensitive tissue
Bioadhesive polymer matrix	Longer residence time and potential dose reduction	More complex regulatory and clinical characterization

High-dose single-treatment ovules can command a convenience premium, but they may have greater local leakage and variable dissolution. Three-day and seven-day regimens may offer better tolerability or lower active loading but require stronger adherence support.

Oral gel excipients

Miconazole oral gel products generally use a structured, mucoadhesive gel containing excipients such as:

• Purified water
• Gelling agents
• Humectants
• Sweeteners
• Flavoring agents
• Alcohol or polyol-based solvents, depending on the product
• Preservatives
• pH adjusters

The main technical challenge is dose uniformity. Miconazole nitrate must remain evenly distributed in the gel during storage and dosing. A mucoadhesive system can increase contact time, but excessive adhesion may impair mouthfeel and swallowing.

Sugar-free systems using sorbitol, xylitol, or other polyols create a diabetic-friendly positioning opportunity. They also introduce risks of gastrointestinal intolerance at high exposure and require careful microbial-control strategy.

Oral gel is commercially available in multiple countries, including products sold under the Daktarin brand. U.S. commercialization is constrained by the absence of broad oral-gel OTC positioning and by the need to address pediatric dosing and choking risks.[4]

How should excipients be selected for miconazole nitrate?

Excipient selection should begin with the delivery objective rather than the active concentration. The formulation must address miconazole nitrate's poor aqueous solubility, crystalline behavior, and sensitivity to the physical structure of the dosage form.

Solubility and dispersion

Miconazole nitrate is practically insoluble in water. A formulator can use one of four broad approaches:

1. Disperse micronized active in a cream or suppository base.
2. Use cosolvents or surfactants to increase apparent solubility.
3. Apply particle-size reduction or wet milling.
4. Use a polymeric or lipid carrier to improve wetting and release.

Complete solubilization is not always commercially optimal. A supersaturated system may produce faster release but can recrystallize during storage. A controlled suspension may offer better stability if particle size, sedimentation, and dose uniformity are controlled.

Particle engineering

Micronization can improve surface area and dissolution without changing the active ingredient. Commercial opportunities include:

• Narrow particle-size distribution
• Reduced agglomeration
• Improved suspension uniformity
• Lower grittiness in vaginal and oral products
• Faster release from suppository and cream bases

Particle-size claims may support formulation differentiation, but they generally need comparative dissolution, microscopy, rheology, and stability data to establish commercial value.

Rheology and residence time

For topical and vaginal products, viscosity must support application without causing excessive drag or poor dose delivery. A shear-thinning system can spread under application force and recover viscosity after administration.

Useful polymer classes include carbomers, cellulose derivatives, polyacrylates, and natural gums. These materials can improve retention but may also bind the active, alter release, raise osmolality, or interact with preservatives.

Preservative strategy

Creams and gels containing water require microbial protection. The selected preservative must remain effective across the product's pH range and must not partition excessively into the oil phase.

Preservative systems should be tested through antimicrobial effectiveness studies, container-closure studies, and in-use simulations. For vaginal products, lower-irritancy systems have commercial value because burning and irritation can reduce adherence.

Preservative-free single-dose packaging can support a premium product strategy. It may also reduce local sensitivity concerns, although it raises packaging and manufacturing costs.

What formulations are commercially differentiated?

The strongest formulation opportunities are those that solve a visible patient or dispensing problem.

Low-mess vaginal products

Leakage is a common usability concern with creams and melting ovules. Product concepts include:

• Lower-volume high-strength ovules
• Bioadhesive gels
• Thermoresponsive systems
• Applicator-free soft capsules
• Single-use prefilled applicators
• Rapid-dissolving tablets

These products require evidence that the formulation improves residence time or patient preference without compromising miconazole release.

Sensitive-skin topical creams

A premium 2% cream can be differentiated through:

• Fragrance-free composition
• Reduced preservative burden
• Lower alcohol content
• Silicone or ester-based skin feel
• Non-greasy after-feel
• Barrier-supportive excipients
• Packaging that reduces contamination

A sensitive-skin product may compete against clotrimazole, terbinafine, ketoconazole, and nonmedicated barrier products. Its commercial advantage must come from tolerability and cosmetic performance because the active ingredient is no longer differentiated by exclusivity.

Foot-care and moisture-control products

Powders, sprays, and fast-drying creams can target athlete's foot and interdigital infections. Talc-free powders using starches, silica, or absorbent mineral systems may support consumer demand for moisture control. Spray products can improve convenience but require attention to flammability, inhalation exposure, actuator performance, and dose delivery.

Combination products

Potential combinations include miconazole nitrate with:

• Hydrocortisone for short-term inflammatory symptoms
• Zinc oxide or other barrier agents
• Moisture-absorbing excipients
• Deodorizing or antiperspirant components
• Vaginal symptom-relief agents

Combination products raise regulatory and clinical complexity. Hydrocortisone combinations require careful labeling because corticosteroid use can mask worsening infection or cause inappropriate prolonged use.

What is the FDA regulatory status of miconazole nitrate?

Miconazole nitrate has established U.S. OTC pathways for topical antifungal and vaginal antifungal products when the formulation and labeling conform to the applicable monographs.

Regulatory issue	Commercial implication
OTC topical antifungal monograph	Enables product development without an individual NDA when requirements are met
OTC vaginal antifungal monograph	Supports generic and private-label vaginal products
New excipient or novel delivery system	May require additional FDA review or an NDA pathway
Combination product	Requires compliance with the applicable combination and labeling requirements
Prescription oral or systemic use	Requires a different regulatory strategy and clinical justification

The FDA Inactive Ingredient Database is an important screening tool for selecting excipients with prior route-specific use. Prior appearance in the database does not by itself establish approval for a new concentration, dosage form, or route.[5]

How many patents protect miconazole nitrate?

Miconazole nitrate is an old small-molecule antifungal and does not have a meaningful composition-of-matter exclusivity barrier in the United States. Core active-ingredient patents are expired. Commercial barriers are more likely to involve:

• Product-specific formulation patents
• Device or applicator patents
• Manufacturing processes
• Particle engineering
• Bioadhesive systems
• Packaging and delivery systems
• Combination-product claims

For standard 2% creams and conventional vaginal products, patent risk is generally lower than regulatory, manufacturing, and channel risk. A new delivery system could create patentable subject matter, but patent durability depends on claim scope, enablement, prior art, and demonstrated performance.

Are Paragraph IV challenges relevant?

Paragraph IV litigation is primarily relevant to abbreviated new drug applications that rely on listed drug patents in the Orange Book. Conventional OTC monograph products generally do not present the same Orange Book patent-certification profile as prescription products.

A company commercializing a standard OTC miconazole nitrate cream or vaginal product is more likely to face:

• Trademark disputes
• Trade-dress issues
• Labeling or compliance actions
• Product-quality recalls
• Retailer qualification requirements
• Private-label price competition

A novel prescription product or individually approved combination could create a more conventional Orange Book and Paragraph IV exposure.

When does miconazole nitrate lose exclusivity?

Miconazole nitrate's core market exclusivity has already expired in major pharmaceutical markets. There is no practical exclusivity cliff comparable to a recent branded small-molecule launch.

Exclusivity category	Current assessment
Active-ingredient patent	Expired
Standard topical generic entry	Mature
Standard vaginal generic entry	Mature
Orphan exclusivity	Not applicable to ordinary miconazole products
Biosimilar exclusivity	Not applicable
New formulation exclusivity	Possible only for an individually approved product
OTC monograph protection	No product-specific exclusivity

What generic entry risks exist?

Generic entry risk is high for conventional products and low for highly differentiated delivery systems only if the developer creates meaningful technical and regulatory barriers.

The main risks are:

• Retail price compression
• Private-label substitution
• Numerous contract manufacturers
• Limited consumer loyalty to a specific brand
• Easy switching among azole antifungals
• Retailer demands for low-cost supply
• Ingredient and packaging commoditization

The strongest defenses are manufacturing consistency, preferred retail placement, clinical preference data, recognizable packaging, patented delivery technology, and reliable global supply.

Which companies compete with miconazole nitrate?

Competition varies by indication and geography.

Competitor	Active ingredient	Main dosage forms	Competitive position
Clotrimazole	Clotrimazole	Cream, vaginal tablet, cream	Direct azole competitor
Terbinafine	Terbinafine hydrochloride	Cream, gel, spray	Strong athlete's-foot competitor
Ketoconazole	Ketoconazole	Cream, shampoo	Dermatology and scalp use
Tioconazole	Tioconazole	Vaginal ointment or ovule	Single-dose vaginal competition
Butenafine	Butenafine hydrochloride	Cream	Topical OTC competitor
Nystatin	Nystatin	Cream, ointment, oral suspension	Alternative antifungal class
Fluconazole	Fluconazole	Oral prescription tablet	Systemic and recurrent candidiasis

Bayer's Canesten products, Johnson & Johnson's Monistat legacy portfolio, and regional generic manufacturers have shaped the competitive market. Brand ownership and product availability vary by country, particularly after portfolio divestitures and licensing arrangements.

What licensing and manufacturing opportunities exist?

Miconazole nitrate is suitable for licensing models based on formulation, geographic rights, private label, and contract manufacturing.

Licensing opportunities

The most bankable licensing structures include:

• Regional rights for a differentiated vaginal product
• Private-label supply agreements with pharmacy chains
• Co-development of a low-mess delivery system
• In-license of a patented applicator or bioadhesive platform
• Portfolio licensing that combines miconazole with other OTC antifungals
• Hospital or institutional supply contracts

The asset should be evaluated on net sales, retailer margin, manufacturing cost, regulatory status, and geographic exclusivity rather than on active-ingredient exclusivity.

Manufacturing barriers

Manufacturing is relatively accessible for standard creams, but quality risks remain significant. Critical process parameters include:

• Active particle dispersion
• Emulsion temperature and shear
• Cooling profile
• Homogeneity
• Fill weight
• Viscosity
• Microbial limits
• Preservative distribution
• Suppository melting behavior
• Container-closure compatibility

For vaginal products, applicator filling and dose delivery can become the main manufacturing constraint. For suppositories, polymorphism and thermal cycling can affect appearance, dissolution, and release.

How strong is the miconazole nitrate patent estate?

The patent estate is weak for standard products and potentially moderate for genuinely differentiated formulations.

Product concept	Patent strength	Commercial barrier
Conventional 2% cream	Low	Manufacturing and retail scale
Conventional vaginal cream	Low	Brand, price, and channel access
Single-dose ovule	Low to moderate	Formulation and packaging
Bioadhesive vaginal gel	Moderate	Clinical and formulation data
Novel particle-engineered product	Moderate	Process reproducibility and claims
Combination product	Moderate	Regulatory and clinical evidence
Novel applicator system	Moderate to strong	Device claims and freedom to operate

Patent value depends on whether the claims cover a reproducible product with measurable benefits. Broad claims directed only to “miconazole plus excipients” are vulnerable to prior art. Narrow claims covering defined ratios, rheology, particle size, release profiles, or device geometry may be more defensible.

What geographic markets offer the best opportunity?

Commercial potential is strongest where OTC access, high fungal-infection prevalence, and fragmented generic supply coincide.

North America

The United States offers large retail distribution and established consumer demand. The market is price competitive, and OTC monograph compliance is central. Premium positioning requires a clear benefit such as lower mess, better skin feel, or improved convenience.

Europe

European markets have strong pharmacy channels and broad use of topical and vaginal azoles. Regulatory strategy varies by country, and national reimbursement and pharmacy practices affect pricing. Canesten and regional generic products create significant competition.

Latin America

Miconazole remains widely recognized in many Latin American markets. Opportunities include affordable branded generics, combination dermatology products, and localized packaging. Regulatory registration and distribution capability are more important than patent exclusivity.

Asia-Pacific

Markets differ sharply in OTC access, prescription control, and consumer familiarity. Oral gel and topical products may have room for expansion, but local manufacturing and registration partnerships can be decisive.

What is the commercial outlook for miconazole nitrate?

Revenue exposure is difficult to isolate because miconazole nitrate is sold through private-label, generic, pharmacy, hospital, and regional branded channels. Standard products usually generate volume rather than high margins.

The most attractive opportunities are:

1. A low-mess, high-retention vaginal formulation.
2. A sensitive-skin 2% cream with differentiated excipients.
3. A sugar-free, palatable oral gel in markets where permitted.
4. A moisture-control spray or powder for foot infections.
5. A contract-manufactured private-label platform.
6. A combination product with clear symptom-management value.
7. A device-enabled product with improved dosing consistency.

The weakest investment case is an undifferentiated 2% cream entering a mature retail category without a cost, channel, or packaging advantage.

Key Takeaways

• Miconazole nitrate is an established, largely commoditized antifungal.
• Core composition-of-matter exclusivity has expired.
• Excipients determine texture, retention, release, tolerability, stability, and patient acceptance.
• The highest-value formulation opportunities are low-mess vaginal products, sensitive-skin creams, improved oral gels, and convenience-focused delivery systems.
• Standard products face high generic and private-label competition.
• Novel excipient systems can support patents only when linked to measurable product performance.
• U.S. OTC monograph pathways can reduce development cost for conventional topical and vaginal products.
• Biosimilar risk is not applicable because miconazole nitrate is a small molecule.
• Paragraph IV exposure is limited for ordinary OTC monograph products but can become relevant for individually approved formulations.
• Manufacturing execution, packaging, regulatory compliance, and retail access are more important than active-ingredient patent protection.

FAQs

Is miconazole nitrate compatible with water-based gels?

It has poor water solubility, so a water-based gel generally requires suspension, cosolvent, surfactant, particle engineering, or a carrier system. Physical stability and dose uniformity must be demonstrated.

Which excipients improve vaginal retention?

Bioadhesive polymers, structured lipid bases, and controlled-release matrices can increase residence time. Their use must be balanced against irritation, leakage, altered release, and preservative compatibility.

Can a new miconazole nitrate cream receive patent protection?

Yes, but protection generally must arise from a novel formulation, particle-engineering method, delivery device, manufacturing process, or combination. A conventional cream base is unlikely to provide strong patent differentiation.

Is miconazole nitrate suitable for a preservative-free product?

Yes, particularly in single-dose packaging. Preservative-free development increases packaging and microbial-control requirements but may support sensitive-skin or vaginal-use positioning.

Does miconazole nitrate have biosimilar competition?

No. Miconazole nitrate is a synthetic small molecule, so market competition comes from generics and alternative antifungal products rather than biosimilars.

References

1. U.S. Food and Drug Administration. (2022). OTC monograph M005: Topical antifungal drug products for over-the-counter human use. https://www.accessdata.fda.gov

2. U.S. Food and Drug Administration. (2022). OTC monograph M030: Vaginal antifungal drug products for over-the-counter human use. https://www.accessdata.fda.gov

3. DailyMed. (2024). Miconazole 3 vaginal cream and miconazole vaginal products: Prescribing and consumer labeling. National Library of Medicine. https://dailymed.nlm.nih.gov

4. McNeil Products Limited. (2023). Daktarin oral gel: Summary of product characteristics. Electronic Medicines Compendium. https://www.medicines.org.uk

5. U.S. Food and Drug Administration. (2024). Inactive ingredient database. https://www.accessdata.fda.gov/scripts/cder/iig/index.cfm

6. United States Pharmacopeial Convention. (2024). Miconazole nitrate monograph. United States Pharmacopeia and National Formulary. https://www.usp.org